Table 3 Visual outcome and uveitis activity at the end of follow-up in different therapy groups in patients with idiopathic uveitis (idio-U) or juvenile idiopathic arthritis associated uveitis (JIA-U). The affected eye or the more active eye with lower visual acuity in bilateral uveitis was analyzed. The numbers represent the number of patients (%) in each treatment category
No DMARD | DMARD | DMARD + Biologics | p-value | ||
|---|---|---|---|---|---|
idio-U | Visual outcome, Snellen, worse eye | 0.642 | |||
<0.5 | 1 (6) | 0 (0) | 0 (0) | ||
0.5–0.8 | 3 (18) | 1 (17) | 2 (50) | ||
>0.8 | 13 (77) | 5 (83) | 2 (50) | ||
SUN classification, n (%) | 0.003 | ||||
0+ | 17 (100) | 3 (50) | 2 (50) | ||
0.5+ | 0 (0) | 3 (50) | 2 (50) | ||
1+ | 0 (0) | 0 (0) | 0 (0) | ||
JIA-U | Visual outcome, Snellen, worse eye | 0.008 | |||
<0.5 | 0 (0) | 1 (3) | 7 (14) | ||
0.5–0.8 | 2 (17) | 2 (7) | 17 (33) | ||
>0.8 | 10 (83) | 26 (90) | 27 (53) | ||
SUN classification, n (%) | 0.088 | ||||
0+ | 12 (100) | 22 (76) | 32 (63) | ||
0.5+ | 0 (0) | 6 (21) | 17 (33) | ||
1+ | 0 (0) | 1 (3) | 2 (4) | ||
Total | Visual outcome, Snellen, worse eye | 0.004 | |||
<0.5 | 1 (3) | 1 (3) | 7 (13) | ||
0.5–0.8 | 5 (17) | 3 (9) | 19 (35) | ||
>0.8 | 23 (79) | 31 (89) | 29 (53) | ||
SUN classification, n (%) | < 0.001 | ||||
0+ | 29 (100) | 25 (71) | 34 (62) | ||
0.5+ | 0 (0) | 9 (26) | 19 (35) | ||
1+ | 0 (0) | 1 (3) | 2 (4) |